Abstract:

In recent years, organ transplantation in our country has witnessed significant growth. However, rejection reactions remain the primary complications affecting graft function and survival rates. Long-term immunosuppressive therapy is the most effective method for preventing rejection reactions. Nevertheless, currently used immunosuppressive agents such as mycophenolate mofetil have notable side effects, leading to many patients being unable to tolerate these side effects, thereby necessitating dose reduction or discontinuation. This, in turn, increases the risk of rejection reactions, ultimately resulting in graft failure. Mizoribine is an immunosuppressant that can concurrently inhibit the proliferation and differentiation of both T lymphocytes and B lymphocytes, with relatively fewer side effects. In recent years, it has been widely employed in the maintenance immunosuppressive therapy following kidney, liver, and other organ transplantations. Although Mizoribine has not yet been applied in the lung transplantation, clinical research evidence from the liver and kidney transplantation present some indications for its application in the lung transplantation, which is worthy of clinical attention and further research.

Key words: Organ transplantation, Mizoribine, Mycophenolate mofetil, Immunosuppressant